Commercialisation

Co-designing the Future of MedTech

Co-designing the future of MedTech ANFF’s Designer in Residence program fosters human-centred design, empowering startups to create user-driven, impactful technological solutions. Innovation alone does not guarantee a product’s success. Even groundbreaking technologies can fail if they overlook everyday consumer needs. High-profile failures like Google Health Records, Segway PT and Evian’s Water Bra illustrate how neglecting […]

Co-designing the Future of MedTech Read More »

Melbourne Medtech startup Haemograph awarded ANFF-C funding

Melbourne healthcare startup Haemograph awarded ANFF-C Gate 2 funding ANFF-C is excited to announce that Haemograph has been awarded Gate 2 pre-seed funding to aid in the commercialisation of its novel blood rheometer. Haemograph is a Melbourne-based start-up revolutionising healthcare with their innovative portable, point-of-care, blood coagulation rheometer. The cutting-edge device measures the viscoelastic properties

Melbourne Medtech startup Haemograph awarded ANFF-C funding Read More »

2024 Showcase highlights ANFF connections with industry and commercialisation

2024 Showcase highlights ANFF connections with industry and commercialisation ANFF facilities provide the critical infrastructure and expertise required to accelerate and de-risk technology development. The availability of these experts and capabilities, including tools for initial prototyping and complete, industry-relevant process trains, adds immense value to early innovations. ANFF and ANFF-C enable researchers to develop new

2024 Showcase highlights ANFF connections with industry and commercialisation Read More »

ANFF-C supports VividWhite in bringing a novel glaucoma treatment device to market

ANFF-C supports VividWhite in bringing a novel glaucoma treatment device to market ANFF-C is excited to announce that VividWhite has been awarded Gate 2 pre-seed funding to aid in the commercialisation of VividFlo, a revolutionary microfluidic medical device that provides a novel approach to glaucoma treatment. Glaucoma is the leading cause of irreversible blindness worldwide,

ANFF-C supports VividWhite in bringing a novel glaucoma treatment device to market Read More »

La Trobe launches AlleSense to commercialise NanoMslide technology

La Trobe University is launching AlleSense, its first major spin-out company with technology that is set to revolutionise medical imaging and potentially save millions of lives. AlleSense has been created to support the commercialisation of technology invented by La Trobe researchers Professor Brian Abbey and Dr Eugeniu Balaur, from the La Trobe Institute for Molecular

La Trobe launches AlleSense to commercialise NanoMslide technology Read More »

NeoGenix wins Gate 2 funding award from ANFF-C

ANFF-C is excited to announce that UTS-born startup NeoGenix Biosciences has been awarded Gate 2 pre-seed funding to aid in the commercialisation of their IVF sperm-selection technology. NeoGenix’s focus is to achieve better outcomes for IVF cycles by improving the reliability and efficiency of sperm isolation and selection, a process that currently uses centrifugation techniques

NeoGenix wins Gate 2 funding award from ANFF-C Read More »

Acknowledgement of Country

ANFF acknowledges the Traditional Owners of Country throughout Australia and pays respect to Elders past and present. We also acknowledge the First Nations people of Australia as engineers and scientists in whose tradition and footsteps we aspire to follow.

Subscribe to our newsletter

Subscribe

© 2024 Australian National Fabrication Facility Limited

ABN: 50 124 231 661

Site by Juno
Follow us:
Linkedin-in